SCHEMBL4628923

SCHEMBL4628923

COc1ccccc1C(C(=O)O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.56
POLB P06746 2/20 0.54
HTT P42858 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA12 O43570 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
CA4 P22748 1/20 0.48
SRC P12931 1/20 0.46
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8539857 0.89 KMT2A (0.50) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL7756307 0.86 POLB (0.50) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL29386813 0.83 CA1 (0.54) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL306964 0.83 CA1 (0.54) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL8825702 0.82 L3MBTL1 (0.47) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL8473051 0.82 PTGS2 (0.64) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL503435 0.82 KMT2A (0.55) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL7885098 0.82 PTGS2 (0.64) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL503436 0.82 KMT2A (0.55) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL6400516 0.82 KMT2A (0.55) KMT2APOLBHTTNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740530-A4 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2008-02-27 EP claimed
JP-2007529530-A 2007-10-25 JP claimed
EP-1740530-A2 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University of the Commonwealth System of Higher Education (US) 2007-01-10 EP claimed
WO-2005089269-A2 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-09-29 WO claimed
US-20080283122-A1 Beta-Substituted Porphyrins CAMPBELL WAYNE MASON 2008-11-20 US disclosed
WO-2006038823-A1 BETA-SUBSTITUTED PORPHYRINS MASSEY UNIVERSITY (NZ) 2006-04-13 WO disclosed
US-5270313-A Treatment of circulatory disorders HOFFMANN-LA ROCHE INC. (US) 1993-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080283122-A1 Beta-Substituted Porphyrins PPOX, HMBS, CRY1 KMT2A 1303/4885POLB 418/4885HTT 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.